Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The closing price of Psyence Biomedical Ltd (NASDAQ: PBM) was $4.92 for the day, down -3.34% from the previous closing price of $5.09. In other words, the price has decreased by -$3.34 from its previous closing price. On the day, 0.14 million shares were traded. PBM stock price reached its highest trading level at $5.72 during the session, while it also had its lowest trading level at $4.81.
Ratios:
Our analysis of PBM’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.64 and its Current Ratio is at 0.64.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PBM now has a Market Capitalization of 2968806 and an Enterprise Value of -257409.
Stock Price History:
The Beta on a monthly basis for PBM is 0.15, which has changed by -0.9863333 over the last 52 weeks, in comparison to a change of 0.092761636 over the same period for the S&P500. Over the past 52 weeks, PBM has reached a high of $699.19, while it has fallen to a 52-week low of $2.92. The 50-Day Moving Average of the stock is 12.68%, while the 200-Day Moving Average is calculated to be -81.94%.
Shares Statistics:
PBM traded an average of 91.00K shares per day over the past three months and 90810 shares per day over the past ten days. A total of 0.09M shares are outstanding, with a floating share count of 0.09M. Insiders hold about 0.00% of the company’s shares, while institutions hold 62.81% stake in the company. Shares short for PBM as of 1748563200 were 40141 with a Short Ratio of 0.44, compared to 1745971200 on 21854. Therefore, it implies a Short% of Shares Outstanding of 40141 and a Short% of Float of 6.98.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
